|
| Population |
Non-hemorrhagic stroke and SEE | Intracranial bleeding |
| Comparison | Risk difference (95% CI) | NNTB
(95% CI) | Risk difference (95% CI) | NNTB
(95% CI) |
|
| All patients | | | | |
| All NOAC versus warfarin | −1 (−2.4 to 0.5) | 1012 (NNTB 418 to ∞ to NNTH 2137) | −3.7 (−5.3 to −3.1) | 271 (190 to 469) |
| Dabigatran versus warfarin | −1.1 (−3.6 to 1.4) | 934 (NNTB 280 to ∞ to NNTH 700) | −4.9 (−6.5 to −3.2) | 206 (153 to 316) |
| Rivaroxaban versus warfarin | −0.9 (−4.1 to 2.2) | 1068 (NNTB 247 to ∞ to NNTH 458) | −2.1 (−3.8 to −0.4) | 469 (263 to 2404) |
| Apixaban versus warfarin | −1.1 (−2.6 to 0.5) | 940 (NNTB 388 to ∞ to NNTH 1984) | −4.3 (−5.9 to −2.7) | 232 (168 to 364) |
|
| Prior stroke or TIA | | | | |
| All NOAC versus warfarin | −0.4 (−3.8 to 3) | 2404 (NNTB 263 to ∞ to NNTH 332) | −5.8 (−10.9 to −2.3) | 173 (92 to 437) |
| Dabigatran versus warfarin | 1.2 (−5.8 to 8.1) | 853 (NNTB 174 to ∞ to NNTH 123) | −8.8 (−13.7 to −3.9) | 113 (73 to 255) |
| Rivaroxaban versus warfarin | −0.5 (−5.3 to 4.3) | 1923 (NNTB 189 to ∞ to NNTH 235) | −1.7 (−4.2 to 0.7) | 583 (NNTB 240 to ∞ to NNTH 1479) |
| Apixaban versus warfarin | −1.7 (−8.9 to 5.5) | 595 (NNTB 112 to ∞ to NNTH 180) | −8.2 (−12.9 to −3.5) | 121 (77 to 283) |
|
| No prior stroke or TIA | | | | |
| All NOAC versus warfarin | −1.1 (−2.7 to 0.4) | 874 (NNTB 377 to ∞ to NNTH 2747) | −3.3 (−4.3 to −2.3) | 305 (232 to 437) |
| Dabigatran versus warfarin | −1.6 (−4.2 to 1) | 613 (NNTB 236 to ∞ to NNTH 1032) | −3.9 (−5.6 to −2.1) | 258 (178 to 478) |
| Rivaroxaban versus warfarin | −1.8 (−5.7 to 2) | 940 (NNTB 388 to ∞ to NNTH 1984) | −2.6 (−4.8 to −0.3) | 392 (207 to 3846) |
| Apixaban versus warfarin | −0.7 (−3 to 1.5) | 1374 (NNTB 337 to ∞ to NNTH 661) | −3.4 (−5 to −1.8) | 293 (201 to 558) |
|
| TTR ≥ 65% | | | | |
| All NOAC versus warfarin | −0.3 (−3.0 to 2.3) | 3086 (NNTB 337 to ∞ to NNTH 441) | −4.5 (−6.4 to −2.6) | 223 (156 to 384) |
| Dabigatran versus warfarin | 1.1 (−2.1 to 4.3) | NNTH 934 (NNTB 467 to ∞ to NNTH 231) | −5.1 (−7.5 to −2.8) | 196 (134 to 363) |
| Rivaroxaban versus warfarin | NA | NA | −3.4 (−6.8 to −0.1) | 296 (148 to 19231) |
| Apixaban versus warfarin | −1.6 (−4.5 to 1.4) | 638 (NNTB 220 to ∞ to NNTH 714) | NA | NA |
|
| TTR < 65% | | | | |
| All NOAC versus warfarin | −3.5 (−6.3 to −0.8) | 283 (159 to 1190) | −2.9 (−5.7 to −0.2) | 344 (177 to 6536) |
| Dabigatran versus warfarin | −3.2 (−6.9 to 0.6) | 316 (NNTB 144 to ∞ to NNTH 1751) | −4.4 (−6.9 to −1.9) | 228 (145 to 516) |
| Rivaroxaban versus warfarin | NA | NA | −1.7 (−3.6 to 0.3) | 601 (NNTB 279 to ∞ to NNTH 3205) |
| Apixaban versus warfarin | −3.6 (−7.2 to 0.1) | 279 (NNTB 138 to ∞ to NNTH 17857) | NA | NA |
|
